H2bisVCap | 205372-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: H2bisVCap
• 英文别名: 1,3-bis(caprolactamyl)butane；1,1'-Butane-1,3-diyldiazepan-2-one；1-[3-(2-oxoazepan-1-yl)butyl]azepan-2-one
• CAS: 205372-24-3
• 化学式: C₁₆H₂₈N₂O₂
• 分子量: 280.411
• InChiKey: STGXTPOCRCBGAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,3-bis(caprolactam-2-on-1-yl)but-1-ene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 methnol 为溶剂， 60.0 ℃ 、3.0 MPa 条件下， 以100%的产率得到H2bisVCap
  参考文献：
  名称：

  A simple chemical model for clathrate hydrate inhibition by polyvinylcaprolactam

  摘要：

  一种二聚体模型化合物为低剂量水合物抑制剂与水的相互作用方式提供了结构上的洞察。

  DOI：

  10.1039/c1cc13556b

文献信息

• Pharmaceutical dosage form comprising a liquid or flowable core composition
  申请人：Abbott GmbH & Co. KG

  公开号：EP2072044A1

  公开（公告）日：2009-06-24

  A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50 % by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4.

  一种药物剂型，包括 a) 液体或可流动的内核；b) 完全包裹所述内核的多糖或蛋白质材料外壳，所述内核包括溶解在药学上可接受的式 (I) 化合物中的活性成分 其中 n 为 3 至 5 的整数，且(i) 至少一种活性成分和式 (I) 化合物至少占组合物重量的 50%；以及 (ii) 组合物的水活性 aw 小于 0.4。
• 1,3-BIS-(N-LACTAMYL)PROPANE UND DEREN PHARMAZEUTISCHE UND KOSMETISCHE VERWENDUNG
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP0934080A2

  公开（公告）日：1999-08-11
• TEST SOLVENT FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES AND GRAFT COPOLYMERS
  申请人：Abbott GmbH & Co. KG

  公开号：EP2536393A2

  公开（公告）日：2012-12-26
• Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
  申请人：Rosenberg Jörg

  公开号：US20090220596A1

  公开（公告）日：2009-09-03

  A composition which comprises a solid or semi-solid matrix having at least one active ingredient uniformly dispersed therein, the matrix comprising at least one pharmaceutically acceptable matrix-forming agent and a 1,3-bis(lactamyl)-butane compound, in particular 1,3-bis(pyrrolidon-1-yl)-butane. The active ingredient is preferably dispersed in the matrix in a state of a solid solution. The matrix-forming agent is preferably a pharmaceutically acceptable polymer. The composition is useful for the manufacture of pharmaceutical dosage forms.
• PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION
  申请人：Rosenberg Jörg

  公开号：US20100297223A1

  公开（公告）日：2010-11-25

  A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4.